Sort   by:  
 Page size 
UnknownMechanisms and potential immune tradeoffs of accelerated coral growth induced by microfragmentation.
Not available
S-EPMC8973463 | biostudies-literature
UnknownInitial experience and cancer detection rates of office-based transperineal magnetic resonance imaging-ultrasound fusion prostate biopsy under local anesthesia.
Not available
S-EPMC9328860 | biostudies-literature
TranscriptomicsSuhB associates with Nus factors to facilitate 30S ribosome biogenesis in Escherichia coli
This experiment consists of two studies. The first where two independent biological replicates of MG1655, MG1655 thyA suhB::thyA and MG1655 thyA nusB::thyA were each grown in LB to mid-exponential phase. RNA-seq and associated data analysis were performed as described previously (Stringer et al., 20...
ORGANISM(S): Escherichia coli str. K-12 substr. MG1655 
2016-01-20 | E-MTAB-4240 | biostudies-arrayexpress
UnknownDirect observation of gold nanoparticle assemblies with the porin MspA on mica.
Not available
S-EPMC2657223 | biostudies-literature
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (L.saccharolytica;Standards assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS2885 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis for resting cells (B.uniformis;C.saccharolyticum assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1757 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria (E.coli;C.saccharolyticum;S.salivarius;E.rectale;L.plantarum;L.lactis assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1627 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1792 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis (FIA-MS) (C.saccharolyticum;E.coli;L.plantarum;L.lactis;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1791 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: duloxetine accumulation at different concentrations (L.saccharolytica;E.coli assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1319 | MetaboLights
Sort   by:  
 Page size